Angiodysplasia secondary prevention

Jump to navigation Jump to search

Angiodysplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Angiodysplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Angiodysplasia secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Angiodysplasia secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Angiodysplasia secondary prevention

CDC on Angiodysplasia secondary prevention

Angiodysplasia secondary prevention in the news

Blogs on Angiodysplasia secondary prevention

Directions to Hospitals Treating Angiodysplasia

Risk calculators and risk factors for Angiodysplasia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nikita Singh, M.B.B.S.[2]

Secondary Prevention

Secondary prevention aims to detect a disease earlier to allow timely intervention to reduce the impacts of the disease after it has already occurred.

For angiodysplasia, the role of vasoactive drugs in the prevention of acute bleeding events and beta blockers to reduce the mesenteric blood flow for secondary prophylaxis is still equivocal.[1]

References

  1. Schwartz J, Rozenfeld V, Habot B (1992). "Cessation of recurrent bleeding from gastrointestinal angiodysplasia, after beta blocker treatment in a patient with hypertrophic subaortic stenosis--a case history". Angiology. 43 (3 Pt 1): 244–8. doi:10.1177/000331979204300309. PMID 1575371.

Template:WS Template:WH